The study, conducted at the First Affiliated Hospital of Fujian Medical University in Fuzhou, China, and registered as clinical trial NCT05188872, prospectively enrolled 98 patients with biochemically confirmed primary aldosteronism. All participants underwent both successful bilateral adrenal venous sampling and 68Ga-Pentixafor PET/CT. The primary analysis focused on 41 patients who had a CT-detected unilateral adrenal adenoma meeting predefined radiological criteria. Of these, 21 were receiving continuous mineralocorticoid receptor antagonist therapy before lateralization testing, while 20 were not, allowing the researchers to directly test whether the drugs distort the imaging signal.

The technical logic behind the comparison is elegant. 68Ga-Pentixafor is a radiolabeled tracer that binds to the chemokine receptor CXCR4, which is overexpressed on the cells of aldosterone-producing adenomas. When injected into a patient, the tracer accumulates in the hormone-producing lesion, and a combined positron emission tomography and computed tomography scan reveals exactly which adrenal gland harbors the overactive tissue. In principle, this offers a non-invasive window into adrenal function that a standard CT scan, which can only show anatomy, cannot provide. The critical question was whether medications that block the mineralocorticoid receptor would blunt this signal and cause the imaging to disagree with AVS.

That question matters because the current guidelines create a genuine clinical dilemma. Mineralocorticoid receptor antagonists such as spironolactone are often the only drugs capable of controlling blood pressure and restoring potassium levels in these patients. Withdrawing them for four or more weeks, as AVS protocols demand, can expose patients to refractory hypertension, dangerous hypokalemia, and heightened cardiovascular risk. For many patients, particularly those with severe disease, the recommended washout period is simply unfeasible. A reliable imaging alternative that works regardless of medication status would therefore fill a real gap in clinical practice.

The researchers’ findings were strikingly reassuring. Baseline aldosterone and serum potassium levels were comparable between the medicated and unmedicated groups, with the only significant biochemical difference being a higher direct renin concentration in the MRA group, an expected pharmacological effect of receptor blockade. When the team determined the optimal imaging threshold, an SUVmax cutoff of 7.60 yielded a maximum Youden index of 0.907, indicating excellent discriminatory performance for identifying the hormone-secreting side. The concordance between 68Ga-Pentixafor PET/CT and AVS was 90.00 percent in the non-medicated group and 85.71 percent in the medicated group, a difference that was not statistically significant.

Importantly, this high agreement held up under further scrutiny. The researchers stratified their results by the laterality of the lesion and by the diameter of the CT-detected adenoma, and the concordance remained consistently high across all subgroups. This robustness matters because adrenal adenomas vary widely in size, and smaller nodules are precisely the ones where anatomical imaging alone is least informative. The fact that tracer uptake continued to lateralize correctly in patients on continuous receptor antagonist treatment suggests that CXCR4 expression on aldosterone-producing cells is not meaningfully suppressed by the drugs, at least within the studied population.

The study did not stop at diagnostic agreement; it also followed patients through treatment. Among those who underwent laparoscopic adrenalectomy, the postoperative clinical and biochemical success rates, whether complete or partial, were 88.89 percent and 94.44 percent in the non-medicated group, compared with 85.71 percent and 92.86 percent in the medicated group. No significant differences were observed between the two cohorts. In other words, patients identified for surgery by the imaging pathway did just as well as those identified through the conventional route, providing an outcome-based validation of the imaging approach rather than a purely radiological one.

The implications extend beyond the technical question of drug washout. Adrenal venous sampling, while accurate in experienced hands, is an invasive procedure with a notable failure rate, since catheterizing the small right adrenal vein is notoriously difficult and success depends heavily on operator expertise and center volume. It is also costly and uncomfortable for the patient. A non-invasive scan that can be performed as an outpatient, without catheters or medication withdrawal, could dramatically simplify the diagnostic pathway for the many patients worldwide whose hypertension is driven by a unilateral aldosterone-producing adenoma and who could be cured with a targeted operation.

The authors are careful to frame the result appropriately. In this selected cohort of primary aldosteronism patients with a CT-detected unilateral adrenal adenoma, 68Ga-Pentixafor PET/CT showed high concordance with AVS, including among patients receiving continuous mineralocorticoid receptor antagonist therapy. They position the technique as a complementary, non-invasive tool for selected patients in whom AVS is technically challenging or in whom medication withdrawal would be clinically unsafe, rather than as an outright replacement for the established gold standard. The cohort size of the primary analysis, 41 patients split into two groups, is modest, and broader validation in larger and more diverse populations will be needed before guidelines change.

Nevertheless, the study represents a meaningful step toward personalized, less invasive care for a disease that affects an estimated five to ten percent of people with hypertension and remains underdiagnosed in many health systems. If larger trials confirm these results, patients with refractory hypertension and a visible adrenal nodule could one day undergo a single PET/CT scan, keep the medications that keep them safe, and proceed directly to curative surgery without ever entering an interventional radiology suite. For a condition whose burden falls disproportionately on patients whose blood pressure resists multiple drugs, that would be a genuinely transformative shift in practice.

Subject of Research: Concordance of 68Ga-Pentixafor PET/CT with adrenal venous sampling for lateralizing primary aldosteronism during mineralocorticoid receptor antagonist treatment

Article Title: Impact of continuous mineralocorticoid receptor antagonist treatment on the concordance between 68Ga-Pentixafor PET/CT and adrenal venous sampling in primary aldosteronism patients with a CT-detected unilateral adrenal adenoma

Article References: Yao, Y., Zhan, Y., Zhang, Q., Lin, K., Chen, Z., Lin, J., Peng, F., Fang, Z., & Cai, H. (2026). Impact of continuous mineralocorticoid receptor antagonist treatment on the concordance between 68Ga-Pentixafor PET/CT and adrenal venous sampling in primary aldosteronism patients with a CT-detected unilateral adrenal adenoma. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02645-9

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02645-9

Keywords: primary aldosteronism, 68Ga-Pentixafor PET/CT, adrenal venous sampling, mineralocorticoid receptor antagonists, aldosterone-producing adenoma, lateralization, hypertension, molecular imaging, CXCR4, adrenalectomy, nuclear medicine, endocrine disorders

Type 2 diabetes mellitus, or T2DM, is a metabolic disorder characterized by chronic hyperglycemia resulting from insulin resistance and progressive failure of insulin-secreting pancreatic beta cells. It accounts for the overwhelming majority of diabetes cases globally, and its prevalence has surged in recent decades, driven by aging populations, urbanization, obesity and sedentary lifestyles. Saudi Arabia sits near the epicenter of this crisis, with national surveys consistently reporting that a substantial fraction of adults live with the condition or its precursor states. Against this backdrop, researchers have increasingly looked beyond lifestyle factors to identify inherited traits that might modulate individual susceptibility.

The ABO blood group system, first described by Karl Landsteiner in 1901, classifies human blood into the A, B, AB and O phenotypes based on the presence or absence of specific carbohydrate antigens on the surface of red blood cells. These antigens are synthesized by glycosyltransferase enzymes encoded by the ABO gene on chromosome 9. The Rhesus system, the second most clinically important blood group classification, is defined largely by the presence or absence of the D antigen. While these systems are best known for their role in transfusion medicine and pregnancy compatibility, a growing body of research has implicated ABO type in a surprising range of conditions, including venous thromboembolism, cardiovascular disease, certain cancers and even susceptibility to some infections.

Previous studies exploring the link between blood groups and diabetes have produced contradictory results, with some reporting elevated risk for particular phenotypes and others finding no association at all. The authors of the new study attribute this inconsistency partly to genetic and geographic differences between the populations examined. Blood group distributions vary considerably across ethnic groups, and the genetic architecture of diabetes risk differs between populations. To address the gap, the research team set out to evaluate the association between ABO and Rh blood groups and the occurrence of T2DM in a Saudi Arabian cohort, a population that had been underrepresented in the existing literature.

The study was designed as a cross-sectional analysis conducted at King Abdulaziz Medical City, spanning January 2019 to December 2023. The investigators enrolled a total of 666 subjects: 350 patients diagnosed with type 2 diabetes and 316 healthy blood donors who served as controls. Because the analysis relied on de-identified retrospective data, the Institutional Review Board of the King Abdullah International Medical Research Centre approved the study and waived the requirement for informed consent. The team then compared the frequency of each ABO and Rh phenotype between the diabetic and control groups, using chi-square tests to detect differences in distribution and multivariable logistic regression to estimate the odds of T2DM associated with each blood type while accounting for potential confounding factors.

The results were striking. The overall distribution of ABO blood groups differed significantly between patients with T2DM and healthy controls, with the difference reaching a p-value of 0.0005. Blood groups A, B and AB were all more frequent among the diabetic patients than among the controls, whereas blood group O was markedly more prevalent in the control group, accounting for 56.2 percent of controls compared with only 43.8 percent of diabetics. When the researchers applied multivariable logistic regression to disentangle the independent contribution of each phenotype, only two associations survived statistical scrutiny. Phenotype B was significantly associated with increased odds of T2DM, with a p-value of 0.017, while blood type O was associated with lower odds of the disease, with a p-value below 0.001.

Notably, the Rhesus blood group showed no significant relationship with diabetes occurrence in this cohort. The researchers also stratified their analysis by sex and by glucose test categories, including fasting blood sugar and hemoglobin A1c, a long-term marker of glycemic control. Neither stratification revealed differences in the prevalence of ABO or Rh phenotypes between diabetics and controls, with all comparisons yielding p-values above 0.05. This suggests that the blood group effect, if real, operates on the overall occurrence of the disease rather than on its severity or glycemic presentation, and that it affects men and women similarly.

What biological mechanisms could underlie such an association? The authors point to several plausible pathways that have been proposed in the broader literature. ABO blood group status influences plasma levels of von Willebrand factor and factor VIII, proteins central to blood coagulation, and group O individuals characteristically have lower levels of both. Because type 2 diabetes is strongly linked to vascular complications and chronic low-grade inflammation, differences in endothelial function, coagulability and inflammatory signaling between blood types could plausibly modulate metabolic risk. ABO antigens are also expressed not only on red blood cells but on the surfaces of many epithelial and endothelial cells and are secreted into body fluids in secretor-positive individuals, raising the possibility of more direct effects on glucose metabolism, gut microbiome composition or insulin signaling pathways. The authors themselves, however, are careful to note that the mechanisms remain unexplored and that their study was not designed to test them.

The researchers conclude that individuals with blood group B appear to have higher odds of T2DM compared with other ABO phenotypes, while those with blood group O show a protective association. They emphasize that further research is needed to validate these findings and to explore the underlying mechanisms in larger, prospective studies. The caution is warranted. Cross-sectional designs capture a single moment in time and cannot establish whether blood type precedes disease onset, and the control group of healthy blood donors may not perfectly represent the general population. Residual confounding by age, body mass index, family history and lifestyle factors cannot be excluded, even with multivariable adjustment. The authors also acknowledge that earlier studies in other populations have yielded inconsistent results, so the pattern observed in this Saudi cohort may not generalize universally.

Nevertheless, the study offers a tantalizing glimpse of how an inherited, easily measurable trait might one day contribute to diabetes risk assessment. Blood group typing is inexpensive, rapid and already performed routinely in clinical settings, so if the association is confirmed and the effect size is meaningful, ABO phenotype could conceivably be incorporated into multifactorial risk models alongside age, weight, family history and metabolic markers. For now, the message for the public remains grounded in established prevention: maintaining a healthy weight, staying physically active and monitoring blood glucose are the proven defenses against type 2 diabetes, regardless of whether one’s red cells carry A, B, both or neither antigen. But as genetic epidemiology continues to probe the unexpected corners of human biology, the idea that a transfusion card could hint at metabolic destiny is no longer quite so far-fetched.

Subject of Research: The association between ABO and Rhesus blood groups and the occurrence of type 2 diabetes mellitus in a Saudi Arabian cohort

Article Title: The association of ABO and Rhesus blood groups with the occurrence of type 2 diabetes mellitus

Article References: Almalki, W., Alghassab, T., Alzahrani, R., Alammar, S., Alotaibi, S., Almowais, L., Alwasel, H., & Alsadhan, A. (2026). The association of ABO and Rhesus blood groups with the occurrence of type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02640-0

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02640-0

Keywords: ABO blood group, Rhesus factor, type 2 diabetes, diabetes risk, blood type O, blood group B, cross-sectional study, Saudi Arabia, logistic regression, endocrine disorders, genetic association, metabolic disease

The study enrolled 160 women of reproductive age at Lady Reading Hospital, dividing them evenly into 80 cases and 80 controls. Cases were diagnosed using the Rotterdam criteria, the internationally accepted framework that requires two of three features: irregular or absent ovulation, clinical or biochemical signs of elevated androgens, and the characteristic polycystic ovarian morphology on ultrasound. Controls were matched by age, a design choice intended to strip away the confounding influence of life stage on both reproductive hormones and vitamin D metabolism. Each participant provided serum for measurement of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, and 25-hydroxyvitamin D, the circulating form of the vitamin that serves as the standard benchmark of nutritional vitamin D status.

The headline numbers are striking. Women with the syndrome had a median 25-hydroxyvitamin D concentration of 12.88 nanograms per milliliter, compared with 30.06 nanograms per milliliter in controls, a difference so large that the associated effect size reached a Spearman correlation coefficient of 0.77, a value rarely seen in human endocrine studies. To put those figures in clinical context, a value below 20 nanograms per milliliter is conventionally labeled deficiency, and below 10 is often considered severe deficiency. The case group’s median therefore sits deep within deficient territory, while the control median falls comfortably in the sufficient range. Thyroid-stimulating hormone told a subtler story: cases averaged 1.67 micro-international units per milliliter against 2.49 in controls, a statistically robust difference with a moderate effect size, yet both medians remained inside the standard laboratory reference interval.

That last point matters, and the authors are careful to underline it. A lower TSH value within the normal range is not the same as thyroid disease, and the study explicitly cautions that the group difference should not be read as evidence of abnormal thyroid function in either direction. What the finding suggests instead is that the hypothalamic-pituitary-thyroid axis may sit at a different set point in women with the syndrome, or that the syndrome and TSH variation share an upstream driver. Speculation about mechanism must remain restrained here, because the design is cross-sectional and associative. The researchers measured hormones at a single time point and cannot say whether low vitamin D and low TSH precede the syndrome, follow from it, or co-occur as parallel consequences of a shared metabolic or inflammatory state.

To move beyond simple group comparisons, the team turned to Firth-penalized binary logistic regression, a statistical technique chosen for a specific technical reason. In datasets where a predictor or combination of predictors nearly perfectly separates cases from controls, a problem statisticians call quasi-complete separation, standard maximum-likelihood logistic regression produces unstable, inflated coefficient estimates that can diverge toward infinity. Firth’s penalization adds a corrective term to the likelihood function, shrinking estimates toward plausible values and yielding finite, interpretable odds ratios even in small or sharply separated samples. This methodological choice lends credibility to the adjusted estimates, which might otherwise have been dismissed as artifacts of overfitting.

The penalized models delivered three independent correlates. Each additional nanogram per milliliter of vitamin D was associated with a 65 percent reduction in the odds of case status, with an adjusted odds ratio of 0.35 and a 95 percent confidence interval of 0.19 to 0.65. Each additional micro-international unit per milliliter of TSH was associated with dramatically lower odds, an adjusted odds ratio of 0.018, though the very wide confidence interval of 0.001 to 0.251 reflects the steepness of the relationship and the penalization required to estimate it. Higher luteinizing hormone, by contrast, pushed odds upward, with an adjusted odds ratio of 1.49 per unit increase. In plain terms, the vitamin D signal and the TSH signal each carried information about case status that the reproductive hormones alone did not capture.

Discrimination analysis sharpened the picture further. When the researchers plotted receiver-operating-characteristic curves, vitamin D alone achieved an area under the curve of 0.945 in this sample, a figure conventionally described as excellent and approaching the separation one would expect from a diagnostic rather than a merely associative marker. TSH managed 0.788 and luteinizing hormone 0.779, both respectable but clearly weaker. The authors resist the tempting leap from discrimination to screening, and rightly so. An in-sample AUC from a case-control design overstates real-world performance, because cases and controls were deliberately balanced and enriched. In the general population, where the syndrome’s prevalence is far lower and the spectrum of vitamin D status is broader, a single blood test would almost certainly perform less impressively.

The vitamin D connection itself is not entirely new to the literature. Previous studies across multiple populations have reported lower 25-hydroxyvitamin D concentrations in women with the syndrome, and proposed mechanisms range from the vitamin’s role in insulin signaling and ovarian steroidogenesis to its influence on anti-Müllerian hormone production and chronic low-grade inflammation. Vitamin D receptors are expressed in ovarian tissue, and the vitamin’s hydroxylase enzymes participate in local steroid hormone synthesis, giving plausible biological routes by which deficiency could interact with the disorder’s core endocrine disturbances. What this study adds is the demonstration that, in a South Asian cohort where deficiency is widespread for reasons of diet, clothing practices, and limited sun exposure, the deficiency signal is nonetheless sharply differentiated between women with and without the syndrome, and that it survives adjustment alongside gonadotropins.

The TSH finding is more novel and more puzzling. Some prior work has suggested a higher prevalence of thyroid autoimmunity and subclinical hypothyroidism among women with the syndrome, which would predict higher rather than lower TSH. The Peshawar cohort shows the opposite direction of shift, albeit within normal limits. One possibility is population-specific variation in iodine status, thyroid antibody prevalence, or body composition, all of which influence TSH. Another is that the association reflects shared regulation, since both TSH secretion and ovarian function are modulated by metabolic signals such as leptin and insulin. Without longitudinal follow-up or mechanistic sampling, these hypotheses remain open. The authors are appropriately explicit that their findings are associative and do not establish causality or screening utility, a restraint that distinguishes the paper from much of the vitamin D literature.

For clinicians and researchers, the study’s practical significance lies in its characterization of a population where the syndrome’s biochemical profile may differ from the Western templates that dominate textbooks. South Asian women face high rates of vitamin D deficiency and distinct metabolic risk patterns, and endocrine reference behavior can vary accordingly. The results argue for measuring 25-hydroxyvitamin D in women evaluated for the syndrome in this region, not as a diagnostic test but as part of a fuller metabolic assessment, and they flag TSH variation within the normal range as a variable worth tracking in future cohorts. Larger prospective studies, ideally with repeated sampling and intervention trials of vitamin D repletion, will be needed to determine whether correcting deficiency alters the syndrome’s trajectory. Until then, this study stands as a carefully executed, statistically disciplined snapshot linking two understudied biochemical markers to one of the most common endocrine disorders of reproductive-age women.

Subject of Research: Associations of vitamin D status and thyroid-stimulating hormone variation with polyendocrine metabolic ovarian syndrome in South Asian women

Article Title: Vitamin D status and TSH variation as independent biochemical correlates of polyendocrine metabolic ovarian syndrome: a case–control study

Article References: Ullah, M. A., Tariq, A., Parvez, K. F., Ashraf, M., Inayat, F., & Zeb, M. A. (2026). Vitamin D status and TSH variation as independent biochemical correlates of polyendocrine metabolic ovarian syndrome: a case–control study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02482-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02482-w

Keywords: polyendocrine metabolic ovarian syndrome, PCOS, vitamin D, TSH, luteinizing hormone, case-control study, penalized regression, endocrine disorders, South Asian women, Rotterdam criteria, 25-hydroxyvitamin D, reproductive endocrinology

The headline number is striking. Across all included studies, the standardized mean difference in hs-CRP levels between people with metabolic syndrome and those without was 0.95, with a 95 percent confidence interval of 0.81 to 1.10, a difference that was statistically significant at p less than 0.001. In practical terms, a standardized mean difference approaching one means that the average person with metabolic syndrome has an inflammatory marker level roughly one full standard deviation above the average healthy control, a substantial separation for a continuous biomarker that varies widely in the general population. The analysis encompassed 71,882 participants in total, of whom 23,945 had metabolic syndrome and 47,937 served as metabolically healthy comparators.

High-sensitivity C-reactive protein is not a mysterious molecule. It is produced by the liver in response to interleukin-6 and other inflammatory cytokines, including tumor necrosis factor alpha, and it rises in the bloodstream whenever the body senses tissue injury or immune activation. What makes the hs-CRP assay valuable is its ability to detect the very low concentrations associated with chronic, smoldering inflammation rather than the dramatic spikes seen during acute infection. For years, researchers have suspected that metabolic syndrome is not simply a disorder of calories and hormones but also an inflammatory state, driven in large part by pro-inflammatory signaling from excess visceral adipose tissue. The new meta-analysis provides the most comprehensive quantitative confirmation to date that this inflammatory signature is detectable in the blood of affected individuals on a global scale.

The research team cast a wide net to assemble their evidence base. They systematically searched PubMed/MEDLINE, EMBASE, Scopus, Web of Science, the Cochrane Library, Epistemonikos and gray literature sources for observational studies that reported both the mean and the standard deviation of hs-CRP among participants with and without metabolic syndrome. To combine the results, the investigators used a random-effects model, the standard approach when studies are expected to differ in population characteristics, laboratory methods and design, and they calculated standardized mean differences with 95 percent confidence intervals as the primary effect measure. Standardization was essential because individual studies measured hs-CRP in different units and with different assays, and the standardized metric allows the magnitude of the difference to be compared on a common scale.

One unavoidable feature of the pooled data was extreme statistical heterogeneity. The I-squared statistic, which describes the proportion of variability in effect estimates attributable to true differences between studies rather than chance, reached 99.49 percent, with a corresponding p value below 0.001. In plain language, almost all of the variation among the studies’ results reflected genuine differences in populations, methods and settings rather than sampling noise. Rather than treating this as a fatal flaw, the researchers responded the way modern meta-analysts typically do: they ran extensive subgroup analyses, stratifying the pooled estimate by geographic region, study design, study setting, fasting status, hs-CRP assay type and the diagnostic criteria used to define metabolic syndrome.

Those subgroup analyses revealed meaningful geographic patterns. The association between metabolic syndrome and elevated hs-CRP was strongest in studies conducted in Europe, where the standardized mean difference reached 2.84, and in Africa, where it reached 2.63, compared with the estimates observed in Asia and the Middle East. The authors of the analysis do not draw firm conclusions about why the effect estimates differ so dramatically across continents, and the observational nature of the underlying data limits any causal interpretation. Plausible contributors include differences in adiposity distribution, diet, genetic background, baseline inflammation from other exposures, assay standardization and the specific diagnostic thresholds used to classify metabolic syndrome in each region. What is clear is that the direction of the association never reversed: in every subgroup examined, people with metabolic syndrome had higher hs-CRP on average than people without it.

Importantly, the association proved robust to the technical choices that often plague biomarker research. The significant difference persisted regardless of whether studies used a clinical design or a community-based one, whether blood samples were drawn fasting or non-fasting, whether hs-CRP was measured by immunoturbidimetric methods or enzyme-linked immunosorbent assay, and whether metabolic syndrome was defined by the National Cholesterol Education Program Adult Treatment Panel III criteria, the International Diabetes Federation criteria or the Joint Interim Statement criteria. This kind of consistency across methodological variations strengthens confidence that the finding is not an artifact of any single laboratory technique or diagnostic framework, even as the sheer magnitude of heterogeneity demands continued caution.

The clinical implications are considerable. Metabolic syndrome affects a large and growing share of adults worldwide and multiplies the risk of type 2 diabetes and cardiovascular disease. If elevated hs-CRP reliably accompanies the syndrome, it could serve as an additional warning sign in clinical practice, helping clinicians identify patients whose metabolic derangement is accompanied by an active inflammatory process, which some evidence links to heightened cardiovascular risk. The authors note that hs-CRP has been proposed as a potential indicator of metabolic syndrome, and their pooled estimate of nearly one full standard deviation lends quantitative weight to that proposal. At the same time, a biomarker that rises with a condition is not automatically a predictor or a cause, and the study’s own conclusions are careful on this point.

That caution is the most scientifically important sentence in the paper. Because every included study was observational, comparing hs-CRP levels between groups at a single point in time or retrospectively, the analysis cannot establish whether inflammation drives the development of metabolic syndrome, whether the metabolic disturbances themselves ignite the inflammation, or whether both arise from shared upstream causes such as visceral fat accumulation, insulin resistance, sedentary lifestyle or poor diet. The authors explicitly state that causal interpretation is constrained by the observational nature of the available data and by the significant between-study heterogeneity, and they call for prospective longitudinal studies to ascertain the temporal connection between hs-CRP and metabolic syndrome. Such studies, which would follow metabolically healthy people with varying baseline hs-CRP levels over years, are the only way to determine whether the biomarker has genuine predictive value beyond its association.

For now, the study stands as a milestone in the effort to quantify the inflammatory dimension of one of the world’s most common metabolic disorders. By aggregating 28 studies and nearly 72,000 participants, the researchers from Wollo University and Debre Berhan University have transformed a scattered literature of inconsistent individual findings into a single, statistically robust summary: metabolic syndrome and elevated high-sensitivity C-reactive protein go together, everywhere that scientists have looked, across every study design, assay method and diagnostic criterion tested. The work, which received no external funding and was published open access under a Creative Commons Attribution 4.0 license, was published on 15 September 2026 with the DOI 10.1186/s12902-026-02532-3. Whether that inflammatory signal will one day help predict who develops diabetes and heart disease, or whether taming it could become a therapeutic target, remains the next great question, and the authors’ call for longitudinal research sets the agenda for answering it.

Subject of Research: The association between high-sensitivity C-reactive protein levels and metabolic syndrome

Article Title: Association between high-sensitivity C-reactive protein and metabolic syndrome: systematic review and meta-analysis

Article References: Habtamu, A., Sebsibe, S., Takele, K., Mengesha, A., Belayhun, E., & Desale, S. (2026). Association between high-sensitivity C-reactive protein and metabolic syndrome: systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02532-3

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02532-3

Keywords: metabolic syndrome, hs-CRP, inflammation, biomarker, systematic review, meta-analysis, cardiometabolic risk, obesity, insulin resistance, C-reactive protein, endocrine disorders, observational studies

The scale of the underlying condition makes the findings consequential. PCOS affects roughly ten percent of women of reproductive age, making it one of the most common endocrine disorders worldwide. Its core features, infertility, hyperandrogenism, and insulin resistance, are well documented in the metabolic literature, but the authors argue that these same physiological disruptions may feed directly into psychological distress. Chronic anovulation and infertility carry profound social and emotional weight, while hyperandrogenic symptoms such as hirsutism and acne can erode body image and self-esteem. Insulin resistance, meanwhile, has been repeatedly linked in broader research to mood disturbance, offering a plausible biological bridge between the ovaries and the brain.

To test that connection rigorously, the researchers followed the PRISMA reporting framework, the international standard for systematic reviews. Their initial search retrieved 209 articles. After removing duplicates, 27 records remained for closer inspection, and 17 full texts were screened against predefined eligibility criteria. Ultimately, ten studies met the quality bar for quantitative synthesis. The team used the odds ratio as its principal statistical instrument, a measure that compares the odds of an outcome occurring in the PCOS group against the odds in controls, with values above one indicating elevated risk. Confidence intervals were calculated at the conventional 95 percent level, meaning there is a one in twenty chance that the true effect lies outside the reported range.

The headline numbers are sobering. Suicidal ideation, the experience of thinking about or planning suicide, was elevated in women with PCOS with an odds ratio of 1.11 and a 95 percent confidence interval of 1.01 to 1.21. That interval sits entirely above the null value of one, which in meta-analytic terms means the association is statistically significant, though modest in magnitude. Depression showed a similar pattern, with an odds ratio of 1.17 and a confidence interval of 1.08 to 1.27, again a statistically reliable but comparatively small elevation. On their own, these figures suggest that for every group of women with PCOS, a slightly larger share experiences depressive symptoms and suicidal thoughts than a comparable group without the syndrome.

The most dramatic result, however, concerned suicide attempts. Here the authors reported a log odds ratio of 4.98 with a 95 percent confidence interval of 1.32 to 18.88. Because the interval is extremely wide, the precision of this estimate is limited, a common feature when the outcome is statistically rare and the number of contributing studies is small. Yet the direction and size of the effect are difficult to dismiss. When the researchers performed a subgroup analysis and removed a single study that contributed disproportionately to heterogeneity, the statistical variability across included trials, the estimate grew even stronger, reaching a log odds ratio of 8.47 with a confidence interval of 7.55 to 9.50. In plain terms, after accounting for the most variable study, the signal linking PCOS to attempted suicide became both more powerful and more precise.

Heterogeneity is the central technical challenge in any meta-analysis, and the authors were transparent about confronting it. When individual studies differ in their populations, diagnostic criteria, and measurement tools, pooling their results can produce estimates that are mathematically valid but clinically ambiguous. The team applied GRADE, the Grading of Recommendations Assessment, Development and Evaluation system, to assess the certainty of their evidence, and they used sensitivity analyses to test whether any single study was driving the overall result. The fact that the suicide attempt association strengthened, rather than collapsed, when the high-heterogeneity study was excluded suggests the finding is not an artifact of one outlier dataset. Still, the authors are careful to note that the evidence base remains limited and, in places, inconsistent, echoing the very gap their review was designed to address.

The diagnostic landscape of PCOS itself complicates interpretation. Over the decades, the field has operated under competing frameworks, including criteria from the National Institutes of Health and the Androgen Excess Society, each of which defines the syndrome slightly differently. Studies included in a meta-analysis may therefore enroll subtly different patient populations, some emphasizing oligomenorrhea and hyperandrogenism, others incorporating polycystic ovarian morphology on ultrasound. Body mass index adds another layer, since obesity is both more prevalent in PCOS and independently associated with depression. Without uniform adjustment for BMI across the included studies, some of the observed psychiatric risk could reflect metabolic comorbidity rather than PCOS per se, a caveat the authors implicitly acknowledge in their call for further research.

What makes the paper clinically urgent is its implication for screening. Mental health assessment is not currently a routine component of endocrine care for PCOS in most settings, where clinical attention tends to focus on menstrual regulation, fertility treatment, and metabolic management. The authors argue that their findings should inform mental health screening and suicide prevention specifically in affected women, effectively proposing that a gynecological or endocrinology appointment could serve as a critical checkpoint for identifying patients at psychological risk. Given that PCOS is diagnosed in young women, often in their teens or twenties, and persists across the reproductive lifespan, the cumulative exposure to untreated depression could be substantial. The authors explicitly state that further prospective studies investigating the prevalence of depression and suicide in PCOS are needed to determine the best treatment approaches.

The biological plausibility of a PCOS-brain connection deserves attention in its own right. Hyperandrogenism, the excess of androgens such as testosterone, has been studied for its effects on mood regulation, with evidence pointing in complex and sometimes contradictory directions. Insulin resistance alters cerebral glucose metabolism and has been implicated in the pathophysiology of depression in general populations. Chronic low-grade inflammation, another hallmark of PCOS, is increasingly recognized as a contributor to depressive disorders. Add the psychological load of infertility, unwanted hair growth, weight gain, and the social pressures that surround them, and the syndrome presents a convergence of biological and psychosocial risk factors that few other common conditions replicate. The meta-analysis does not disentangle these mechanisms, but it establishes the epidemiological signal that future mechanistic work must now explain.

For the estimated one in ten women of reproductive age living with PCOS, the study reframes the condition as a whole-body, whole-mind disorder rather than a purely gynecological one. The authors, who self-funded the work and declared no competing interests, published their findings open access, making the evidence freely available to clinicians and patients alike. Their synthesis of ten studies, filtered from an initial pool of 209, represents one of the most focused quantitative examinations to date of suicidality in this population. The message for medicine is direct: the psychiatric dimensions of PCOS, particularly the elevated risk of suicide attempts, can no longer be treated as incidental. Whether routine screening in endocrine and obstetric clinics can translate these statistics into lives saved is now the question that prospective research, and health systems, must answer.

Subject of Research: Association between polycystic ovary syndrome and depression and suicidality in women

Article Title: Suicidality and depression in women with polycystic ovary syndrome: a systematic review and meta-analysis

Article References: Albalawi, Y., & Mirghani, H. (2026). Suicidality and depression in women with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02554-x

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02554-x

Keywords: polycystic ovary syndrome, PCOS, depression, suicidal ideation, suicide attempts, meta-analysis, systematic review, mental health, hyperandrogenism, insulin resistance, women's health, endocrine disorders

Medullary thyroid carcinoma is not the common papillary variety that dominates thyroid cancer statistics and fuels much of the active surveillance debate. It arises from the parafollicular C cells of the thyroid, the cells that produce calcitonin, and it behaves differently from its more indolent cousins. It does not respond to radioiodine therapy, it secretes measurable biomarkers that track its burden, and it can metastasize to cervical lymph nodes early in its course. When such a tumor is caught while still under one centimeter in diameter, it earns the designation of microcarcinoma, and it is precisely in this small, seemingly harmless form that the disease increasingly presents. As ultrasound technology improves and thyroid imaging becomes more common, more of these minute tumors are being found, and clinicians are left with a growing population of patients for whom the natural history is poorly charted.

The research team, led by Yuanmeng Li, Naishi Li, Weigang Zhao, and Xiaolan Lian, combed through their institutional records and identified 75 cases of medullary thyroid microcarcinoma. Within that group, they focused on a subset of 20 patients whose diagnosis and surgical treatment had been delayed and for whom baseline ultrasound imaging of adequate quality existed. For these patients, the observational period before surgery exceeded six months, with a median duration of 27 months. That is a substantial stretch of time for a tumor to do whatever it is going to do, and it gave the investigators a rare longitudinal window into the behavior of an entity that is usually excised quickly and studied only in retrospect.

What the ultrasound scans revealed was striking. Seventy-five percent of the delayed-surgery patients, 15 of the 20, showed sonographic evidence that their microcarcinoma nodules had grown during the observation period, a proportion with a 95 percent confidence interval spanning roughly 53 to 89 percent. When the researchers compared the final nodule volumes with the initial measurements, the difference was statistically robust, with p values below 0.001. In plain terms, these were not static lesions idling in the thyroid gland. During a median of more than two years without intervention, the majority of these tumors expanded, and the volume change was unmistakable rather than a borderline statistical artifact.

Growth alone, however, does not tell a clinician whether a tumor has become more dangerous. To address that question, the team turned to the pathological and biochemical signatures that medullary thyroid carcinoma leaves behind. They stratified their patients using a 5 millimeter threshold, a cut point that divides the microcarcinoma range into its smallest and largest halves. The results were consistent across every measure they examined. Tumors larger than 5 millimeters were associated with higher preoperative levels of calcitonin and carcinoembryonic antigen, the two biomarkers that serve as the workhorses of medullary thyroid cancer surveillance. They also carried a greater incidence of lymph node metastasis, more advanced TNM staging, and a lower rate of biochemical cure after surgery, meaning a lower likelihood that postoperative biomarker levels fell to undetectable territory. Every one of these comparisons reached statistical significance at p values below 0.01.

Correlation analysis reinforced the same story along a continuous gradient rather than a binary divide. Tumor size in this cohort was positively associated with preoperative calcitonin levels, with a correlation coefficient of 0.357 and a p value of 0.022, and with carcinoembryonic antigen levels, which showed an even stronger association at r equals 0.428 and p equals 0.003. Size also correlated with lymph node metastasis at r equals 0.388, with TNM stage at r equals 0.416, and with worse overall outcome at r equals 0.330, the latter with a p value of 0.006. None of these correlations is overwhelming in isolation, and the study’s own authors are careful to note that tumor size and observation time are intertwined in this setting, making it impossible to fully disentangle whether the tumors that grew were intrinsically more aggressive or whether the passage of time itself allowed indolent lesions to progress. But the direction of every association points the same way: bigger tumors, in this disease, mean more disease.

The biological logic behind these findings is worth unpacking. Calcitonin secretion is a function of the number of malignant C cells present, so a growing tumor should, and does, produce a rising biomarker signal. Cervical lymph node metastasis in medullary thyroid carcinoma is known to correlate with primary tumor size, and the 5 millimeter threshold identified here aligns with a broader literature suggesting that risk in this disease accrues continuously rather than in discrete jumps. What makes the new study notable is not that it overturns established biology but that it documents the temporal dimension directly. Most of what is known about medullary thyroid microcarcinoma comes from surgical specimens examined after the fact, snapshots of tumors at the moment of removal. Watching these tumors across a median of 27 untreated months provides something those snapshots cannot: evidence that the clock matters.

The clinical context amplifies the significance. Active surveillance, the strategy of monitoring small thyroid nodules with serial ultrasound rather than operating immediately, has gained genuine traction for papillary thyroid microcarcinoma, where large Japanese cohort studies have shown that the majority of these lesions never grow to a clinically meaningful size. That evidence base has created a certain cultural momentum, a sense among some patients and clinicians that small thyroid cancers in general can be watched safely. The new findings are a pointed reminder that medullary thyroid carcinoma is a different biological entity. There is no equivalent evidence base supporting surveillance for medullary microcarcinoma, and this study now provides the first direct, if retrospective and limited, evidence that waiting carries measurable risk. The authors stop short of claiming that every microcarcinoma will progress, and indeed a quarter of their delayed-surgery cohort showed no growth, but the burden of proof has shifted.

Several caveats deserve honest acknowledgment. The study is retrospective and comes from a single center, which means selection bias is a real possibility; the very fact that these patients experienced delayed diagnosis and surgery suggests their tumors may have been clinically silent or initially mischaracterized, a circumstance that may not generalize to all microcarcinomas. Twenty patients is a small sample, and the confidence intervals around the 75 percent growth figure are correspondingly wide. The authors themselves note that the clinical implications of their findings require confirmation in future studies, ideally prospective ones with standardized imaging intervals and larger, multi-center cohorts. The study was approved by the Ethics Committee of Peking Union Medical College Hospital and conducted in accordance with the Declaration of Helsinki, and it was supported by funding from the Chinese Academy of Medical Sciences, the National Natural Science Foundation of China, and related institutional programs, lending it institutional credibility even as its scale remains modest.

Even with those limitations, the message for clinical practice is difficult to ignore. Medullary thyroid microcarcinoma should not be presumed to remain stable during an untreated interval, the authors conclude, and once the diagnosis is suspected, prompt workup and timely surgery are the prudent default. For a disease that announces itself through calcitonin and CEA, biomarkers that can be measured with a simple blood draw, and that can be imaged with the ultrasound machines already present in every endocrinology clinic, the barriers to early action are low. What this study adds is the urgency: in the roughly two years that separated baseline imaging from surgery for these patients, three quarters of their tumors grew, and the ones that grew larger arrived at the operating room with higher biomarker levels, more nodal disease, more advanced staging, and poorer chances of biochemical cure. Small, in medullary thyroid cancer, does not mean stationary, and the new data suggest that the window in which these tumors are truly micro may be one worth closing deliberately rather than watching drift by.

Subject of Research: Tumor growth and outcomes in medullary thyroid microcarcinoma during delayed surgery

Article Title: Tumor growth in medullary thyroid microcarcinoma during delayed surgery: a single-center study

Article References: Li, Y., Chai, X., Liu, H., Zhang, H., Li, X., Li, B., Chen, X., Zhou, J., Li, N., Zhao, W., & Lian, X. (2026). Tumor growth in medullary thyroid microcarcinoma during delayed surgery: a single-center study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02606-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02606-2

Keywords: medullary thyroid microcarcinoma, thyroid cancer, tumor growth, calcitonin, carcinoembryonic antigen, lymph node metastasis, delayed surgery, active surveillance, ultrasound, TNM staging, biochemical cure, endocrine disorders

The adrenal glands are small but vital endocrine organs that produce cortisol, aldosterone, and other hormones essential for blood pressure regulation, salt and water balance, and the body’s response to stress. Because of their exceptionally rich blood supply and their unusual venous drainage into a single central vein, the adrenal glands are surprisingly vulnerable to a rare but well-described catastrophe: thrombosis of the adrenal vein, which cuts off the outflow of blood, causes hemorrhagic infarction, and leads to bleeding into the gland itself. In other words, the hemorrhage that appears on a CT scan is not a simple bleed but the end result of a clot that choked off the gland’s circulation. This mechanism explains why adrenal hemorrhage is a recognized, if uncommon, complication of antiphospholipid syndrome, an autoimmune condition in which the immune system mistakenly produces antibodies against phospholipid-binding proteins in the blood.

What makes the Palestinian patient’s case so unusual is that the hemorrhage affected only one adrenal gland. Adrenal insufficiency, the clinical state that arises when the glands fail to produce enough cortisol, is far more commonly associated with bilateral adrenal involvement, because the remaining healthy gland can usually compensate when only one side is damaged. In this patient, however, a large right adrenal hematoma was accompanied by severe biochemical derangement, including a profoundly low serum sodium concentration and a morning serum cortisol level of just 2.8 micrograms per deciliter, a value far below the threshold expected in a critically ill patient. These findings raised immediate concern that the single damaged gland had left him functionally unable to mount a cortisol response, a condition that can rapidly become life-threatening if untreated.

The diagnostic journey began with computed tomography, which revealed the large right adrenal hematoma and effectively excluded other causes of the patient’s abdominal pain. But the laboratory workup added the crucial pieces of the puzzle. His platelet count was low, a finding known as thrombocytopenia that is common in antiphospholipid syndrome. More tellingly, his activated partial thromboplastin time, or aPTT, a standard measure of blood clotting, was markedly prolonged. In most clinical contexts, a prolonged aPTT suggests a bleeding tendency, and one might expect such a patient to hemorrhage more easily. Yet in antiphospholipid syndrome, the prolongation is a laboratory artifact caused by antibodies that interfere with the phospholipid reagents used in the test, even as the patient’s actual physiology is prothrombotic. This is the famous lupus anticoagulant paradox: a test that suggests poor clotting in a patient whose disease is defined by clotting.

To distinguish between a clotting factor deficiency and an inhibitor, the team performed a mixing study, in which the patient’s plasma is combined with normal pooled plasma. If the prolonged clotting time corrects with the addition of normal plasma, the problem is a missing factor; if it fails to correct, an inhibitor is present. In this patient, the mixing study failed to correct the aPTT, pointing squarely toward an inhibitor. Follow-up testing confirmed a positive lupus anticoagulant, and subsequent assays revealed high-titer anticardiolipin antibodies and high-titer anti-beta2-glycoprotein I antibodies. Together with the lupus anticoagulant, these three positive tests constitute the triple-positive antiphospholipid antibody profile, the highest-risk serological pattern in the syndrome, associated with the greatest likelihood of thrombotic events. The combination of adrenal hemorrhage, thrombocytopenia, and the characteristic coagulation abnormalities established the diagnosis of antiphospholipid syndrome presenting for the first time through its adrenal complication.

Once hematology specialists reviewed the case, they favored APS-associated thrombotic adrenal injury as the underlying mechanism, and treatment was initiated accordingly. The patient received therapeutic anticoagulation, first with enoxaparin, a low-molecular-weight heparin delivered by injection, and later transitioned to warfarin, an oral vitamin K antagonist that remains the mainstay of long-term anticoagulation in antiphospholipid syndrome. At the same time, the adrenal insufficiency was treated with hydrocortisone, a replacement glucocorticoid that restores the missing cortisol, and fludrocortisone, a mineralocorticoid that helps the body retain sodium and maintain blood pressure. This dual approach addressed both faces of the disease simultaneously: preventing further clots with anticoagulation while replacing the hormones the damaged gland could no longer produce.

The clinical course was encouraging. During follow-up, the patient showed progressive improvement in his symptoms, his laboratory values normalized, including his kidney function and electrolytes, and repeat imaging demonstrated a marked reduction in the size of the adrenal hematoma. The recovery underscores an important point about adrenal hemorrhage in the context of antiphospholipid syndrome: with prompt anticoagulation and appropriate hormone replacement, even a dramatic presentation can resolve substantially, and patients can return to good health. It also highlights the value of multidisciplinary care, since the case required coordinated input from internal medicine, endocrinology, hematology, and radiology to arrive at the correct diagnosis and treatment plan.

For the wider medical community, the authors argue that this case carries a clear message. When clinicians encounter a patient with unexplained adrenal hemorrhage, particularly when it is accompanied by thrombocytopenia, evidence of adrenal dysfunction, and a markedly prolonged aPTT, antiphospholipid antibody testing should be high on the differential. The alternative is a dangerous diagnostic delay, in which the hemorrhage is attributed to trauma or other causes and the underlying prothrombotic disorder goes untreated, leaving the patient exposed to further clots in the adrenal glands, the brain, the lungs, or the deep veins of the legs. Equally important is the early recognition of adrenal insufficiency itself, because untreated cortisol deficiency in a stressed, febrile patient can precipitate an adrenal crisis, a medical emergency characterized by hypotension, shock, and death if glucocorticoid replacement is not given immediately.

The case also illustrates the subtlety of the antiphospholipid syndrome’s laboratory signature. Lupus anticoagulant antibodies earned their name because they were first identified in patients with lupus and because they prolong clotting tests in a test tube, yet they are among the strongest laboratory predictors of thrombosis in the body. This inversion of expectations, in which a bleeding test predicts clotting, is one of the most counterintuitive phenomena in clinical medicine, and cases like this one, where the paradox plays out in a single organ, provide vivid teaching material for physicians in training. The triple-positive profile identified in this patient, with all three major antiphospholipid antibody tests positive at high titer, marks him as requiring careful, long-term anticoagulation management and monitoring for future thrombotic risk.

Published as an open-access report with the patient’s written informed consent, the study adds to the limited literature on unilateral adrenal hemorrhage as the initial manifestation of antiphospholipid syndrome. It demonstrates that clinically significant adrenal insufficiency can develop even when only one gland is visibly affected, that the hemorrhagic appearance of adrenal injury should not obscure its thrombotic origin, and that a simple mixing study followed by targeted antibody testing can unravel a diagnosis that might otherwise remain hidden. For a young man whose vague symptoms of fever, pain, and fatigue masked a rare autoimmune catastrophe, the systematic application of basic clinical reasoning, from CT imaging to coagulation studies to antibody panels, made the difference between a mysterious illness and a treatable disease with a clear path to recovery.

Subject of Research: Adrenal hemorrhage and adrenal insufficiency as the initial presentation of triple-positive antiphospholipid syndrome

Article Title: Unilateral adrenal hemorrhage and adrenal insufficiency as the initial presentation of triple-positive antiphospholipid syndrome: a case report

Article References: Alshamisti, M. I., Deeb, N., Almasalmah, A., Amayre, S., Kurdi, L., Atawnah, S. I., & Ibriwesh, M. (2026). Unilateral adrenal hemorrhage and adrenal insufficiency as the initial presentation of triple-positive antiphospholipid syndrome: a case report. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02609-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02609-z

Keywords: adrenal hemorrhage, adrenal insufficiency, antiphospholipid syndrome, triple-positive antiphospholipid antibodies, lupus anticoagulant, thrombocytopenia, cortisol, anticoagulation, case report, endocrine disorders, hydrocortisone, warfarin

Polyendocrine metabolic ovarian syndrome, or PMOS, is the updated name for what clinicians have long called polycystic ovary syndrome, or PCOS. The renaming reflects a growing recognition that the condition is not simply an ovarian disorder but a systemic disturbance spanning the endocrine and metabolic systems, involving irregular hormone signaling, insulin resistance, and altered menstrual function. It is the most common endocrine disorder among women of reproductive age, and its first signs frequently appear during adolescence, when the hypothalamic-pituitary-ovarian axis is still maturing. That developmental window is precisely why researchers are increasingly interested in identifying risk symptoms early, before metabolic consequences such as insulin resistance, weight gain, and long-term reproductive complications become entrenched.

The new study, led by Xinyang Ren of Shanghai Pinghe School’s IB High School Program together with Anran Xue of Southwest Medical University and Dongxia Zhai of Changhai Hospital at Naval Medical University, focused on a group that has been largely invisible in PCOS research: post-menarchal girls in rural China. Most epidemiological work on the syndrome has been conducted in urban tertiary care settings among adult women seeking treatment for infertility or menstrual irregularity. Adolescents in rural areas, by contrast, seldom come to clinical attention, meaning their symptoms often go unrecognized for years.

To fill that gap, the research team administered a cross-sectional survey to 404 female students aged 12 to 16 years at a middle school in rural Shandong Province. The instrument was a 26-item questionnaire designed to capture menstrual characteristics, self-reported symptoms, lifestyle behaviors, levels of parental support, and awareness of the syndrome. All participants had already begun menstruating, which allowed the researchers to assess cycle regularity and related features. The study received ethics approval from the Shanghai Changhai Hospital Ethics Committee, and informed consent was obtained from both the participants and their legal guardians, in accordance with the Declaration of Helsinki.

Rather than treating risk as a binary variable, the investigators classified participants into three strata of PMOS-related risk, a design that allowed them to look for dose-response relationships between potential risk factors and symptom burden. This stratified approach is methodologically important: if a factor such as sleep deprivation is genuinely linked to risk, its association should strengthen as risk level rises, a pattern that is harder to dismiss as statistical noise than a single comparison between affected and unaffected groups.

The results were sobering. Of the 404 girls surveyed, 85, or 21.0 percent, were classified as at risk of PMOS-related symptoms. That figure means roughly one in five rural adolescent girls in the sample reported a constellation of symptoms associated with the syndrome. Across the risk strata, the researchers observed statistically significant dose-response gradients for three factors in particular: perceived stress, insufficient sleep, and parental indifference, with all three associations reaching the conventional threshold of p less than 0.05. In other words, the girls reporting the highest levels of stress, the shortest or most disrupted sleep, and the least engaged parents were consistently the ones clustered in the higher-risk categories.

When the moderate- and high-risk groups were combined for logistic regression analysis, two factors emerged as independent predictors of at-risk status after adjustment. Insufficient sleep was associated with roughly a doubling of the odds of being in the at-risk group, with an adjusted odds ratio of 1.91 and a 95 percent confidence interval of 1.17 to 3.11. Parental indifference carried an even stronger signal, with an adjusted odds ratio of 2.55 and a 95 percent confidence interval of 1.11 to 5.89. These confidence intervals exclude the null value of 1, indicating that the associations are statistically significant even after accounting for other measured variables. The finding on parental indifference is particularly noteworthy because it suggests that the family environment, not just individual biology or behavior, may play a measurable role in whether adolescent girls develop or report PMOS-related symptoms.

The awareness data may be the study’s most consequential contribution. In the moderate-risk group, 84.8 percent of participants showed low awareness of the syndrome. That figure describes girls who were already reporting the very symptoms clinicians use to flag possible PMOS, yet who largely lacked the knowledge to recognize those symptoms as anything out of the ordinary. The implications are straightforward: symptoms that could prompt earlier evaluation and lifestyle modification instead pass unremarked, potentially delaying diagnosis well into adulthood. Reproductive health literacy, the researchers suggest, is a modifiable target, and school-based education could be a practical vehicle for raising it in rural settings where specialist gynecological care is scarce.

The mechanistic plausibility of the sleep finding deserves attention. Sleep restriction in adolescents is known to dysregulate the hypothalamic-pituitary-adrenal axis, elevate evening cortisol, and worsen insulin sensitivity, all of which intersect with the endocrine and metabolic disturbances that define PMOS. Chronic sleep insufficiency has also been linked in adult studies to increased androgen levels and menstrual irregularity, the hallmark features of the syndrome. While a cross-sectional survey cannot establish whether poor sleep contributes to symptom development or whether girls with emerging symptoms sleep worse, the dose-response gradient and the adjusted odds ratio together make a compelling case that sleep is a variable worth targeting in future longitudinal and interventional research.

The parental indifference finding points in a different but complementary direction. Adolescent menstrual health is a topic that remains stigmatized or simply unspoken in many rural households, and girls whose parents are disengaged may be less likely to have irregular cycles noticed, discussed, or followed up with medical care. Parental indifference may therefore operate both as a stressor in its own right and as a barrier to early recognition of symptoms, compounding the low awareness the girls themselves reported. The authors caution that these associations merit further investigation rather than definitive causal interpretation, but they argue that both insufficient sleep and low parental engagement are actionable targets for school- and family-based interventions.

What makes the study unusual is its provenance as much as its content. The first author conducted the research while still a high school student, working with clinical collaborators at Naval Medical University, and the project received no specific funding. The team thanked the students of Laizhou Tushan Middle School for their participation and the school administration for facilitating data collection. The work is published open access under a Creative Commons license, making the full dataset of findings available to researchers and educators in the regions where the problem is most acute.

The broader significance lies in what the study implies about global adolescent health. PMOS affects an estimated portion of women of reproductive age worldwide, but its adolescent presentation is notoriously difficult to diagnose because irregular cycles are common in the first years after menarche and diagnostic criteria were largely developed for adults. Studies like this one, which focus on self-reported risk symptoms rather than definitive diagnosis, offer a way to identify populations that need earlier education and screening without overpathologizing normal adolescent physiology. The message from rural Shandong is that the groundwork of prevention, awareness, adequate sleep, and engaged family support, may need to begin years before most clinicians currently start looking.

Subject of Research: PMOS-related risk symptoms and awareness among rural Chinese adolescent girls

Article Title: Polyendocrine metabolic ovarian syndrome-related risk symptoms and awareness among rural Chinese adolescent girls

Article References: Ren, X., Xue, A., & Zhai, D. (2026). Polyendocrine metabolic ovarian syndrome-related risk symptoms and awareness among rural Chinese adolescent girls. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00494-4

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00494-4

Keywords: polyendocrine metabolic ovarian syndrome, PCOS, adolescent health, rural China, menstrual health, reproductive health literacy, sleep deprivation, parental support, cross-sectional study, endocrine disorders, Shandong Province, women's health

The research, published in Discover Mental Health, was conducted by a team based at City St George’s University, the South West London and St George’s Mental Health NHS Trust, St George’s Hospital and collaborating London institutions. It took the form of a retrospective case record review, meaning the investigators systematically combed through the clinical notes of 282 adults who had received a neurologist-confirmed diagnosis of functional neurological disorder, often abbreviated to FND, while attending a tertiary neuropsychiatry service. Tertiary services sit at the top of the referral pyramid, treating the most complex and treatment-resistant cases, so the cohort represents a heavily clinically burdened population rather than the full spectrum of FND in the community.

The numbers that emerged from the record review were striking. Metabolic disorders appeared in the notes of 25.5 percent of the cohort, while endocrine disorders were recorded in 24.8 percent. Among the individual conditions, diabetes mellitus was the most common, affecting 12.4 percent of patients, followed closely by thyroid dysfunction at 11.7 percent and hypertension at 10.6 percent. For a condition whose clinical presentation is dominated by neurological symptoms, the sheer prevalence of classic cardiometabolic and hormonal disease in this population is a reminder that FND rarely travels alone. Clinicians managing these patients, the authors suggest, are dealing with whole-body health as much as with brain function.

This matters because comorbidity is not a passive backdrop in neurological psychiatry. Conditions such as diabetes and thyroid disease can themselves produce fatigue, cognitive complaints and sensory disturbance, and their presence can complicate diagnosis, prolong referral pathways and shape the rehabilitation strategies that patients are offered. Conversely, living with a disabling functional disorder may influence diet, physical activity and healthcare engagement, all of which feed into metabolic risk. The relationship is almost certainly bidirectional, which is precisely why mapping the landscape of physical comorbidity in FND has become an increasingly urgent task for researchers.

Methodologically, the team went beyond simple prevalence counts. They examined whether particular metabolic and endocrine conditions clustered with particular FND subtypes, using Fisher’s exact tests corrected for the false discovery rate, a statistical adjustment designed to prevent spurious associations from slipping through when many comparisons are made simultaneously. Across this corrected analysis, several nominal associations surfaced between FND subtypes and comorbid conditions, but none survived the correction. That negative result is worth taking seriously: it suggests that the broad categories of metabolic and endocrine disease are distributed fairly evenly across the FND population seen at this service, rather than attaching themselves to specific symptom groups in a way the data could confirm.

One association, however, stood out enough to warrant a second, more careful look. The study examined patients with functional cognitive disorder, or FCD, a subtype of FND characterised by distressing problems with memory and concentration that lack a neurodegenerative explanation. Dyslipidaemia, the abnormal level of blood fats such as cholesterol, was recorded in 29.2 percent of patients with FCD compared with just 7.4 percent of the rest of the cohort. Expressed as an odds ratio, this corresponded to a nearly fivefold unadjusted increase in odds of dyslipidaemia among those with functional cognitive symptoms, with an unadjusted p value of 0.003.

The researchers then applied multivariable logistic regression, adjusting for age and sex, two of the strongest demographic drivers of cholesterol abnormalities. The association attenuated but held: the adjusted odds ratio was 3.75, with a 95 percent confidence interval of 1.29 to 10.90 and a p value of 0.015. In plain terms, even after accounting for who the patients were, the link between functional cognitive disorder and dyslipidaemia remained statistically visible. Yet the authors are careful to label the finding exploratory, because the corresponding unadjusted association did not survive the earlier false discovery rate correction, and the analysis was not designed or powered to test this single hypothesis in isolation.

Why might blood fat abnormalities and functional cognitive symptoms travel together? The authors do not claim a causal mechanism, and the retrospective design forbids any confident inference about direction. It is conceivable that dyslipidaemia contributes to vascular changes that interact with cognitive vulnerability, or that the association reflects shared pathways such as chronic stress, inflammation or lifestyle disruption that influence both lipid metabolism and functional symptom generation. It is equally possible that referral patterns, diagnostic Work-ups, or chance in a modestly sized cohort explain the signal. Larger, prospectively designed controlled studies comparing FND patients with matched controls are the clear next step, and the study’s authors say exactly that in their conclusions.

The study also carries practical implications for the clinic. Roughly one in four patients in the cohort had a recorded metabolic or endocrine condition, which means that a routine neuropsychiatry assessment for FND is, in effect, also an opportunity to screen for diabetes, thyroid dysfunction, hypertension and lipid abnormalities. The authors note that reproductive comorbidities were captured alongside metabolic and endocrine ones, filling a gap they identify in the literature, where such profiles have been underexplored. If clinicians overlook these conditions, patients may find that treatable physical problems are attributed to their functional diagnosis, or vice versa, either of which can delay appropriate care. Integrated models that treat FND within the whole of a patient’s physiology, rather than as a neurological label floating free of the body, are the direction in which the field appears to be moving.

Equally important is what the study does not show. Because every participant had FND and the analysis was largely descriptive and within-cohort, the work cannot establish whether people with FND have more metabolic and endocrine disease than the general population, nor can it determine whether any of these conditions increase the risk of developing FND, worsen its course, or simply coexist with it. The absence of associations surviving multiple-comparison correction counsels against overinterpreting subtype patterns beyond the exploratory FCD signal. Still, by providing a carefully quantified baseline from a tertiary neuropsychiatry cohort, the study gives future investigators a concrete target: prospective cohorts with control groups, standardised metabolic screening and sufficient numbers to test whether the dyslipidaemia and functional cognitive disorder link is real, and if so, what it means for how these patients are investigated and treated.

Subject of Research: Metabolic, endocrine and reproductive comorbidities in adults with functional neurological disorder

Article Title: Metabolic, endocrine and reproductive comorbidities in functional neurological disorder: a retrospective study of a tertiary neuropsychiatry cohort

Article References: Tamilson, B., Telikapalli, N., Poller, A., Nihoyannopoulos, L., Puspuri, K., Tse, J. T. K., Coebergh, J., & Agrawal, N. (2026). Metabolic, endocrine and reproductive comorbidities in functional neurological disorder: a retrospective study of a tertiary neuropsychiatry cohort. Discover Mental Health. https://doi.org/10.1007/s44192-026-00603-4

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00603-4

Keywords: functional neurological disorder, metabolic comorbidity, endocrine disorders, dyslipidaemia, diabetes mellitus, thyroid dysfunction, hypertension, functional cognitive disorder, neuropsychiatry, retrospective study, reproductive health, comorbidity

The headline finding is stark: insulin resistance was significantly more common among women with PCOS than among their matched counterparts under every one of the three diagnostic criteria the researchers applied. Using fasting serum insulin as the yardstick, 77.8 percent of the PCOS group crossed the threshold for insulin resistance compared with 58.3 percent of controls. When the homeostasis model assessment, or HOMA, was used—calculated as fasting plasma glucose in millimoles per litre multiplied by fasting insulin in microunits per millilitre and divided by 22.5—half of the PCOS participants qualified as insulin resistant, against just 16.7 percent of controls. The glucose-to-insulin ratio, a more direct gauge of peripheral insulin sensitivity, told a similar story, identifying insulin resistance in 44.4 percent of women with PCOS versus 16.7 percent of the control group, with all comparisons reaching statistical significance at p below 0.01.

The divergence among these three metrics is itself scientifically instructive. Fasting insulin, the authors note, has a tendency to overestimate insulin resistance, while HOMA can underestimate it, because the model assumes a stable relationship between hepatic glucose output and insulin secretion that does not always hold in practice. The glucose-to-insulin ratio, by contrast, provides a more direct quantitative readout of insulin-stimulated glucose disposal and the completeness of hepatic glucose suppression, which is why the team adopted a cutoff of less than 4.5 as its primary classification tool, consistent with thresholds validated previously in obese women and in women with PCOS. Insulin resistance was flagged whenever any single criterion was abnormal—fasting insulin above 64.4 picomoles per litre, HOMA above 3.82, or the ratio below 4.5—and the consistency of the signal across all three measures lends considerable weight to the conclusion that Saudi women with PCOS carry a genuine and substantial metabolic burden.

That burden extends deep into the hormonal machinery of the syndrome. Women with PCOS in the study exhibited luteinizing hormone concentrations of 9.4 plus or minus 8.6 international units per litre, more than double the 4.1 plus or minus 3.7 observed in controls, a difference significant at p below 0.001. The ratio of luteinizing hormone to follicle-stimulating hormone, a classical marker of the disordered gonadotropin signalling seen in PCOS, was likewise markedly elevated, and the gap was most pronounced among women who were both non-obese and insulin resistant. Correlation analysis sharpened the picture further: glucose-to-insulin ratio scores correlated positively with luteinizing hormone levels (r equal to 0.45, p below 0.01) and with the luteinizing hormone to follicle-stimulating hormone ratio (r equal to 0.38, p below 0.05), indicating that the worse a woman’s peripheral insulin sensitivity, the more deranged her gonadotropin profile tended to be.

This coupling is biologically coherent. Hyperinsulinemia is known to amplify gonadotropin dysregulation, driving the ovaries toward increased androgen production and thereby feeding the hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology that define the syndrome. Insulin acts synergistically with luteinizing hormone on ovarian theca cells, stimulating steroidogenesis, while simultaneously suppressing hepatic synthesis of sex hormone-binding globulin, raising the fraction of circulating free androgen. The Jeddah data, showing insulin-resistant women with PCOS bearing fasting insulin levels of 34.6 plus or minus 11.8 microunits per millilitre against 22.4 plus or minus 2.5 in insulin-resistant controls, with higher HOMA values and lower glucose-to-insulin ratios, suggest that this vicious cycle operates with particular intensity in the Saudi cohort. Clinically, the implication is that metabolic intervention—through lifestyle modification or insulin-sensitizing therapy—may do double duty, easing not only diabetes and cardiovascular risk but also the endocrine symptoms that bring many women to the clinic in the first place.

Bone health, by contrast, emerged as a surprisingly quiet frontier. Despite the profound metabolic and hormonal alterations documented in the PCOS group, dual-energy X-ray absorptiometry using a GE Healthcare Lunar iDXA system revealed no statistically significant differences in bone mineral density or T-scores at the lumbar spine or femoral neck between women with PCOS and controls. Classification by World Health Organization criteria—normal for T-scores above minus one, osteopenia between minus one and minus two point five, and osteoporosis below minus two point five—showed comparable skeletal status across the cohort. This null result aligns with a growing body of international literature, including studies reporting comparable hip bone geometry and unaltered bone mineral density in women with PCOS, and it complicates the hypothesis that insulin resistance, which has been implicated in impaired bone quality in other populations, inevitably translates into measurable skeletal deficits in premenopausal women.

Yet the bone story may simply be unfinished. Stratified analyses hinted at a non-significant trend toward higher T-scores among obese women with PCOS, a pattern the authors interpret through the well-established influence of body weight on bone mass. Mechanical loading from excess adiposity, together with adipokine-mediated effects on bone metabolism, may exert a protective influence on the skeleton—at least temporarily—that offsets any catabolic pressure from insulin resistance or hormonal disruption. Whether that protection persists through menopause, when the loss of estrogen removes a major skeletal safeguard, is a question the current study, limited to women aged 24 to 44, cannot answer. The researchers are careful to frame these stratified signals as trends requiring confirmation rather than established findings, particularly given the exploratory design and the absence of formal correction for multiple comparisons.

Vitamin D adds another layer of regional complexity. Mean serum 25-hydroxyvitamin D concentrations were strikingly low in both groups—21.1 plus or minus 15.1 nanomoles per litre in women with PCOS and 22.0 plus or minus 19.5 in controls, a non-significant difference—mirroring the widespread hypovitaminosis D documented across the Middle East. Parathyroid hormone levels were similarly comparable between groups. Because vitamin D status did not differ between cases and controls, the investigators deliberately excluded it as a covariate in their primary bone analyses, reasoning that it was unlikely to confound between-group comparisons. Even so, they acknowledge that individual-level effects of vitamin D on skeletal outcomes cannot be entirely ruled out, and they call for larger, longitudinal studies with adjusted analytical models to clarify whether vitamin D metabolism interacts with insulin resistance and obesity to shape bone health in PCOS over time.

The study’s design carries inherent constraints that temper, though do not diminish, its contribution. As a cross-sectional investigation conducted between December 2018 and June 2019, it captures a single moment in time and cannot establish whether insulin resistance causes the observed hormonal derangements, results from them, or arises in parallel from shared underlying mechanisms. The sample of 72 cases, recruited prospectively from the infertility clinic at King Abdulaziz University Hospital, is modest, and its restriction to a single ethnic group in one city limits generalizability. Twenty-nine initially recruited women were excluded for thyroid disorders, other endocrine conditions, ovarian tumours, severe obesity, pregnancy, psychological conditions, or withdrawal of consent, underscoring the care taken to isolate a clean PCOS phenotype.

What the study loses in causal inference, however, it gains in precision and relevance. By triangulating three independent measures of insulin resistance in a carefully matched cohort, it demonstrates beyond reasonable doubt that the metabolic burden of PCOS among Saudi women is heavy, that it tracks closely with gonadotropin disruption, and that bone mineral density, at least in the reproductive years, is not yet paying a measurable price. The authors argue that early identification and management of insulin resistance—alongside obesity—should be central to the clinical care of women with PCOS in regions where metabolic and endocrine disorders are highly prevalent, a prescription aimed at heading off type 2 diabetes, cardiovascular disease, and any delayed skeletal consequences before they take root. With PCOS prevalence in Saudi Arabia reported at roughly sixteen percent, the public health stakes of that prescription are considerable, and the Jeddah findings give clinicians in the region a clear, evidence-based target at which to aim.

Subject of Research: Insulin resistance, hormonal profiles, and bone mineral density in Saudi women with polycystic ovary syndrome

Article Title: Polycystic ovary syndrome, insulin resistance, and bone health in Saudi women: a cross-sectional study

Article References: Albaik, M., McGuigan, F. E. A., Altyar, A. E., Khan, J. A., & Akesson, K. E. (2026). Polycystic ovary syndrome, insulin resistance, and bone health in Saudi women: a cross-sectional study. Archives of Osteoporosis, 21(1), Article 139. https://doi.org/10.1007/s11657-026-01707-8

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01707-8

Keywords: polycystic ovary syndrome, insulin resistance, bone mineral density, Saudi women, HOMA, glucose-to-insulin ratio, luteinizing hormone, vitamin D deficiency, obesity, osteoporosis, DXA, endocrine disorders